Cargando…

Scaffold Hopping of α-Rubromycin Enables Direct Access to FDA-Approved Cromoglicic Acid as a SARS-CoV-2 M(Pro) Inhibitor

The COVID-19 pandemic is still active around the globe despite the newly introduced vaccines. Hence, finding effective medications or repurposing available ones could offer great help during this serious situation. During our anti-COVID-19 investigation of microbial natural products (MNPs), we came...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alhadrami, Hani A., Sayed, Ahmed M., Al-Khatabi, Heba, Alhakamy, Nabil A., Rateb, Mostafa E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8229550/ https://www.ncbi.nlm.nih.gov/pubmed/34198933 http://dx.doi.org/10.3390/ph14060541

Ejemplares similares

Olive-Derived Triterpenes Suppress SARS COV-2 Main Protease: A Promising Scaffold for Future Therapeutics
por: Alhadrami, Hani A., et al.
Publicado: (2021)

Catalytic Control of Spiroketal Formation in Rubromycin Polyketide Biosynthesis
por: Toplak, Marina, et al.
Publicado: (2021)

Neoechinulin A as a Promising SARS-CoV-2 M(pro) Inhibitor: In Vitro and In Silico Study Showing the Ability of Simulations in Discerning Active from Inactive Enzyme Inhibitors
por: Alhadrami, Hani A., et al.
Publicado: (2022)

Microbial Natural Products as Potential Inhibitors of SARS-CoV-2 Main Protease (M(pro))
por: Sayed, Ahmed M., et al.
Publicado: (2020)

Cecropin A Improves the Antibacterial Activity of Hen Egg White Lysozyme against Challenging Salmonella enterica Serovars
por: Alhadrami, Hani A., et al.
Publicado: (2022)

FDA Approvals of Biologics in 2022
por: Martins, Alexander C., et al.
Publicado: (2023)

In Silico-Based Discovery of Natural Anthraquinones with Potential against Multidrug-Resistant E. coli
por: Alhadrami, Hani A., et al.
Publicado: (2022)

Drugs, Devices, and the FDA: Part 2: An Overview of Approval Processes: FDA Approval of Medical Devices
por: Van Norman, Gail A.
Publicado: (2016)

Computational development of rubromycin-based lead compounds for HIV-1 reverse transcriptase inhibition
por: Bernardo, Carlos E.P., et al.
Publicado: (2014)

Streptomyces iakyrus TA 36 as First-Reported Source of Quinone Antibiotic γ–Rubromycin
por: Charousová, Ivana, et al.
Publicado: (2023)

Bioguided Isolation of Cyclopenin Analogues as Potential SARS-CoV-2 M(pro) Inhibitors from Penicillium citrinum TDPEF34
por: Thissera, Bathini, et al.
Publicado: (2021)

An acetyltransferase controls the metabolic flux in rubromycin polyketide biosynthesis by direct modulation of redox tailoring enzymes
por: Toplak, Marina, et al.
Publicado: (2022)

Why Did the FDA Approve These Advertisements?
por: Oaks, David
Publicado: (2006)

FDA approved ready to use phenylephrine
por: Bhatia, Pradeep Kumar, et al.
Publicado: (2021)

An insider's perspective on FDA approval of aducanumab
por: Wang, Yaning
Publicado: (2023)

Alchemical analysis of FDA approved drugs
por: Orsi, Markus, et al.
Publicado: (2023)

Flavonoids as Potential anti-MRSA Agents through Modulation of PBP2a: A Computational and Experimental Study
por: Alhadrami, Hani A., et al.
Publicado: (2020)

Scaffold Searching of FDA and EMA-Approved Drugs Identifies Lead Candidates for Drug Repurposing in Alzheimer’s Disease
por: Shityakov, Sergey, et al.
Publicado: (2021)

Development and Evaluation of a Self-Nanoemulsifying Drug Delivery System for Sinapic Acid with Improved Antiviral Efficacy against SARS-CoV-2
por: Alhadrami, Hani A., et al.
Publicado: (2023)

FDA approved drugs as potential Ebola treatments
por: Ekins, Sean, et al.
Publicado: (2015)

FDA-approved medications that impair human spermatogenesis
por: Ding, Jiayi, et al.
Publicado: (2016)

FDA approved antibacterial drugs: 2018-2019
por: Andrei, Stefan, et al.
Publicado: (2019)

The current landscape of the FDA approved companion diagnostics
por: Jørgensen, Jan Trøst
Publicado: (2021)

FDA-Approved Oximes and Their Significance in Medicinal Chemistry
por: Dhuguru, Jyothi, et al.
Publicado: (2022)

Timeline of FDA-Approved Targeted Therapy for Cholangiocarcinoma
por: Cho, Su Min, et al.
Publicado: (2022)

FDA approved vaccines for monkeypox: Current eminence
por: Chopra, Hitesh, et al.
Publicado: (2022)

Potential COVID-19 papain-like protease PL(pro) inhibitors: repurposing FDA-approved drugs
por: Kouznetsova, Valentina L., et al.
Publicado: (2020)

Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States
por: Yang, Fan, et al.
Publicado: (2023)

Machine Learning with Quantum Seagull Optimization Model for COVID-19 Chest X-Ray Image Classification
por: Ragab, Mahmoud, et al.
Publicado: (2022)

Deep Ensemble Model for COVID-19 Diagnosis and Classification Using Chest CT Images
por: Ragab, Mahmoud, et al.
Publicado: (2021)

Quantitative analysis on the characteristics of targets with FDA approved drugs
por: Sakharkar, Meena K., et al.
Publicado: (2007)

FDA-Approved Natural Polymers for Fast Dissolving Tablets
por: Alam, Md Tausif, et al.
Publicado: (2014)

Repurposing FDA-approved drugs for anti-aging therapies
por: Snell, Terry W., et al.
Publicado: (2016)

A systematic analysis of FDA-approved anticancer drugs
por: Sun, Jingchun, et al.
Publicado: (2017)

First vaccine approval under the FDA Animal Rule
por: Beasley, David W C, et al.
Publicado: (2016)

A Comprehensive Map of FDA-Approved Pharmaceutical Products
por: Zhong, Hao, et al.
Publicado: (2018)

THPdb: Database of FDA-approved peptide and protein therapeutics
por: Usmani, Salman Sadullah, et al.
Publicado: (2017)

New FDA approved antibacterial drugs: 2015-2017
por: Andrei, Stefan, et al.
Publicado: (2018)

Immunotherapy for Breast Cancer: First FDA Approved Regimen
por: Soare, Georgiana R., et al.
Publicado: (2019)

Novel targeted drugs approved by the NMPA and FDA in 2019
por: Wang, Wenjing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_04hmt9u62n3lf1rdrl092sqm8q